Synthesis of novel triazole/isoxazole functionalized 7-(trifluoromethyl)pyrido[2,3-d]pyrimidine derivatives as promising anticancer and antibacterial agents

• Published in: Bioorganic & medicinal chemistry letters 2016-06, Vol.26 (12), p.2927-2930
• Main Authors: Naresh Kumar, R., Jitender Dev, G., Ravikumar, N., Krishna Swaroop, D., Debanjan, B., Bharath, G., Narsaiah, B., Nishant Jain, S., Gangagni Rao, A.
• Format: Article
• Language: English
• Subjects: 1,3-Dipolar cycloaddition; Anti-Bacterial Agents - chemical synthesis; Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Anticancer; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Cell Line, Tumor; Cell Proliferation - drug effects; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gram-Negative Bacteria - drug effects; Gram-Positive Bacteria - drug effects; Humans; Isoxazole; Isoxazoles - chemical synthesis; Isoxazoles - chemistry; Isoxazoles - pharmacology; Microbial Sensitivity Tests; Molecular Structure; Pyrido[2,3-d]pyrimidine; Sharpless conditions; Structure-Activity Relationship; Triazole; Triazoles - chemical synthesis; Triazoles - chemistry; Triazoles - pharmacology
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2016.04.038

Novel 1,2,3-triazole/isoxazole functionalized pyrido[2,3-d]pyrimidine derivatives 6a–c, 7a–h and 8a–e were prepared and screened for anticancer activity. Compounds 7d and 7h showed highest activity. All the compounds also screened for antibacterial activity and identified promising compounds. Further evaluated for minimum inhibitory concentration to validate the data. [Display omitted] A series of novel 1,2,3-triazole/isoxazole functionalized pyrido[2,3-d]pyrimidine derivatives 6a–c, 7a–h and 8a–e were prepared in series of synthetic steps. All the compounds screened for the anticancer activity against four human cancer cell lines using Nocodazole as standard. Compounds 7d and 7h showed highest activity against PANC-1 (pancreatic cancer) and A549 (lung cancer) cell lines respectively and more than standard. All the compounds also screened for antibacterial activity using Rifampicin and Ciprofloxacin as standards and identified promising compounds further evaluated for minimum inhibitory concentration to validate the data.